AU2016345462A1 - D-proline derivatives as SAP depleting agent - Google Patents

D-proline derivatives as SAP depleting agent Download PDF

Info

Publication number
AU2016345462A1
AU2016345462A1 AU2016345462A AU2016345462A AU2016345462A1 AU 2016345462 A1 AU2016345462 A1 AU 2016345462A1 AU 2016345462 A AU2016345462 A AU 2016345462A AU 2016345462 A AU2016345462 A AU 2016345462A AU 2016345462 A1 AU2016345462 A1 AU 2016345462A1
Authority
AU
Australia
Prior art keywords
compound
sap
formula
disease
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016345462A
Other languages
English (en)
Inventor
Alexis Denis
Olivier Mirguet
Jérôme Toum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2016345462A1 publication Critical patent/AU2016345462A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016345462A 2015-10-27 2016-10-25 D-proline derivatives as SAP depleting agent Abandoned AU2016345462A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1518950.9 2015-10-27
GBGB1518950.9A GB201518950D0 (en) 2015-10-27 2015-10-27 Compound
PCT/EP2016/075632 WO2017072099A1 (en) 2015-10-27 2016-10-25 D-proline derivatives as sap depleting agent

Publications (1)

Publication Number Publication Date
AU2016345462A1 true AU2016345462A1 (en) 2018-04-26

Family

ID=55130261

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016345462A Abandoned AU2016345462A1 (en) 2015-10-27 2016-10-25 D-proline derivatives as SAP depleting agent

Country Status (12)

Country Link
US (1) US10328052B2 (enExample)
EP (1) EP3368532B1 (enExample)
JP (2) JP6789288B2 (enExample)
KR (1) KR20180067559A (enExample)
CN (1) CN108368095B (enExample)
AU (1) AU2016345462A1 (enExample)
BR (1) BR112018008582A2 (enExample)
CA (1) CA3002710A1 (enExample)
ES (1) ES2781550T3 (enExample)
GB (1) GB201518950D0 (enExample)
RU (1) RU2018119120A (enExample)
WO (1) WO2017072099A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
ES2182203T3 (es) * 1997-10-31 2003-03-01 Hoffmann La Roche Derivados de d-prolina.
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201407506D0 (en) * 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound

Also Published As

Publication number Publication date
RU2018119120A (ru) 2019-11-28
EP3368532B1 (en) 2020-01-15
US10328052B2 (en) 2019-06-25
CA3002710A1 (en) 2017-05-04
KR20180067559A (ko) 2018-06-20
JP2018531967A (ja) 2018-11-01
CN108368095A (zh) 2018-08-03
GB201518950D0 (en) 2015-12-09
US20190060274A1 (en) 2019-02-28
JP7053762B2 (ja) 2022-04-12
JP2021035963A (ja) 2021-03-04
BR112018008582A2 (pt) 2018-10-30
ES2781550T3 (es) 2020-09-03
WO2017072099A1 (en) 2017-05-04
JP6789288B2 (ja) 2020-11-25
CN108368095B (zh) 2021-06-08
EP3368532A1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
US9737505B2 (en) Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
IL292522A (en) Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi
US10597385B2 (en) Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
EP4347044A2 (en) Egfr degraders to treat cancer metastasis to the brain or cns
Tanaka et al. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis
WO2023165459A1 (en) Compounds as sars-cov-2 inhibitors
EP3368532B1 (en) D-proline derivative as sap depleting agent
CN114025766A (zh) 用于抑制gapdh的噁噻嗪化合物
WO2026030341A1 (en) Zervimesine for treating neurodegenerative disease
KR20260049797A (ko) 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
CA3061787C (en) Compositions for treating neurodegenerative diseases
HK40067738A (en) Oxathiazin compounds for inhibiting gapdh

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted